Luke B Sloan, MD Dermatology - Procedural Dermatology Medicare: Accepting Medicare Assignments Practice Location: 917 11th St, Hood River, OR 97031 Phone: 541-386-2517 Fax: 541-386-1919 |
News Archive
Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.
In 1973, a group of birth defects associated with prenatal ethanol exposure was clinically recognized as Fetal Alcohol Syndrome (FAS). Since then, scientists have come to realize that alcohol can cause a wide range of birth defects; these are collectively referred to as Fetal Alcohol Spectrum Disorders (FASD).
Investigators who studied a group of recreational marathon runners have established that strenuous exercise such as running a marathon can damage the heart muscle. Although they found the effect is temporary and reversible, they warn that these effects are more widespread in less fit distance runners and that recreational distance runners should prepare properly before marathons.
Pfizer Inc. announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004).
Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study designed to investigate its BreathID test to non-invasively detect primary liver cancer, also known as Hepatocellular Carcinoma (HCC).
› Verified 8 days ago